New Directions in Metastatic CRC Treatment: Roundtable Discussions

This program was presented as a continuing education symposium for oncology nurses during the ONS APN Conference and ONS 9th Annual IOL.

Saturday, November 15, 2008
7:00 – 9:00 pm (Pacific Time Zone)
Grand Ballroom C
Sheraton Seattle Hotel
Seattle, Washington

Release Date: November 2008
Expiration Date: October 2009
Estimated Time to Complete Activity: 2.0 hours (Adobe Flash Player and Adobe Acrobat Reader required)

Target Audience

This activity has been designed to meet the educational needs of patient care oncology nurses.

Purpose

To educate oncology nurses on current treatment standards and symptom management for metastatic colorectal cancer (CRC).

Program Overview

Advances in therapeutic and diagnostic techniques as well as the availability of several new active agents have revolutionized the treatment of CRC in recent years. This symposium will present pivotal research developments in CRC, including emerging data on novel agents, positive and negative predictors of response to these agents, and how this information may ultimately translate into individualized patient treatment and improved outcomes.

A CRC physician key opinion leader will begin the symposium with an overview of treatment standards and outstanding clinical questions. As the principles of adult learning are often breached by the inability of participants to engage thought leaders and colleagues in the discussion of questions, practice patterns, and complicated patient scenarios, following this overview, IMER will provide a dynamic learning opportunity via intimate roundtable discussions on three actual patients with CRC: newly diagnosed advanced CRC, recurrent metastatic CRC, and CRC with liverlimited metastases. At each roundtable, CRC treatment standards of care based on disease stage, patient performance status, age, previous treatment exposure, and genetic factors will be discussed as they relate to the pertinent case. Because this program is dedicated to oncology nursing practice, symptom management will be a major focus.

Learning Objectives

Upon completion of this program, participants should be better able to:

Identify the latest research on the use of systemic therapy for metastatic CRC
Identify future directions of care, including the use of molecular markers in clinical decision-making
Evaluate emerging data on the use of calcium and magnesium for peripheral neuropathy
Describe optimal strategies for the management of treatment toxicities related to commonly used CRC regimens
Identify appropriate systemic regimens for CRC patients with liver-limited metastases

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. IMER, Bristol-Myers Squibb Company and ImClone Systems Incorporated do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of IMER, Bristol-Myers Squibb Company and ImClone Systems Incorporated. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest

IMER requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by IMER for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Faculty

Linda M. Penwarden, MN, RN, AOCN®
St. Luke’s Mountain States Tumor Institute

Ms. Penwarden is an oncology clinical nurse specialist at St. Luke’s Mountain States Tumor Institute, Boise, Idaho. She received her master’s degree in nursing from the University of Washington, Seattle. Her research interests include non-Hodgkin’s lymphoma, metastatic CRC, and non-small cell lung cancer. Ms. Penwarden has given hundreds of oncology-based presentations throughout the United States. She is an active member of the Oncology Nursing Society, American Nurses Association, and Idaho Nurses Association.

Linda M. Penwarden, MN, RN, AOCN®, reported a financial interest/relationship or affiliation in the form of: Consultant, Amgen, Inc.; Speakers’ Bureau, Pfizer, Inc. and Genentech BioOncology.

Axel Grothey, MD
Mayo Clinic College of Medicine

Dr. Grothey is a professor of Oncology at the Mayo Clinic College of Medicine in Rochester, Minnesota. He received his medical degree from Ruhr-Universitat Bochum, Germany. His research interests include the role of antiangiogenesis agents in the treatment of colorectal cancer. Dr. Grothey has published and lectured extensively on a variety of oncology-related topics and served on the review or editorial boards of oncology journals such as the British Journal of Cancer, Cancer Research, and Clinical Oncology. He is a member of the Minnesota Medical Association, American Association for Cancer Research, and European Society for Medical Oncology.

Axel Grothey, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, sanofi-aventis U.S., Genentech BioOncology, Roche Laboratories, and Bristol-Myers Squibb Company.

Robin M. Sommers, MSN, RN, NP
Dana-Farber Cancer Institute

Ms. Sommers is a nurse practitioner at the Division of Gastrointestinal Oncology of the Dana-Farber Cancer Institute in Boston. She obtained her master of science in nursing from the University of Massachusetts in Worcester. Ms. Sommers is a frequent presenter on various aspects of colorectal and gynecologic cancers. She is active in several professional organizations, including the Massachusetts Nurses Association, Oncology Nursing Society, and Massachusetts Coalition of Nurse Practitioners.

Robin M. Sommers, MSN, RN, NP, reported a financial interest/relationship or affiliation in the form of: Speakers' Bureaus, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, and Amgen, Inc.

Catherine Handy, PhD, RN, AOCN^®
St. Vincent’s Comprehensive Cancer Center

Dr. Handy is an oncology clinical nurse specialist at St. Vincent’s Comprehensive Cancer Center in New York City. She is also a faculty member for the Health Advocacy Program at Sarah Lawrence College in Bronxville, New York. She received her doctorate in nursing from New York University. She has been an oncology nurse for more than 30 years, working in acute care, ambulatory care, radiation therapy, stem cell transplant, and homecare. Dr. Handy’s research interests include side-effect prevention and management, pain management, and end-of-life issues. She lectures nationally on these and other cancer-related topics.

Catherine M. Handy, PhD, RN, AOCN^®, reported no areas of conflict.

Theresa W. Gillespie, PhD, RN
Emory University School of Medicine

Dr. Gillespie is an associate professor in the Department of Surgery as well as the Department of Hematology and Medical Oncology at Emory University School of Medicine. She also serves as director of the Division of Health Services Research at the Veterans Affairs Medical Center in Atlanta. She obtained her doctorate in the Division of Educational Studies at Emory University. Dr. Gillespie’s research interests include the prevention and control of symptoms associated with cancer and cancer therapy. With more than 27 years experience in clinical oncology, she has published and presented extensively. Dr. Gillespie is a manuscript reviewer for numerous journals, including Oncology Nursing Forum, Oncology Clinical Practice, and Journal of General Internal Medicine.

Theresa W. Gillespie, PhD, RN, reported no areas of conflict.

Pamela H. Viale, MS, RN, CS, ANP, AOCNP^®
University of California, San Francisco

Ms. Viale is an assistant clinical professor in the Department of Physiological Nursing at the University of California, San Francisco, where she also received her master’s degree in oncology nursing. She has lectured nationally and written journal articles on various oncology nursing topics. She is also a member of the editorial advisory board for the ONCOLOGY Nurse Edition publication, and is an expert panel member for the ManageCRC.com Web site, which provides information on CRC for nursing professionals.

Pamela Hallquist Viale, MS, RN, CS, ANP, AOCNP^®, reported a financial interest/relationship or affiliation in the form of: Consultant, Meniscus Educational Institute, Novartis Pharmaceuticals Corporation, and Bristol-Myers Squibb Company; Speakers' Bureau, IMER, Meniscus Educational Institute, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Amgen, Inc., and Merck & Co., Inc.

Accreditation Statements

This educational activity for 2.0 contact hours will be provided by IMER. IMER is an approved provider of continuing education by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

IMER is approved by the California Board of Registered Nursing, Provider Number 14763 for 2.4 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Safeguards Against Commercial Bias

IMER affirms that the content and format of its CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, IMER employs several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CE activities sponsored by IMER to ensure adherence to the American Nurses Credentialing Center’s criteria and operational requirements and the Accreditation Council for Continuing Medical Education’s content validation statements and resolution of any actual or perceived conflict of interest that exist. We employ three metrics as we review materials:

1. Fair balance

a.
Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter

b.
No single product or service is overrepresented when other equal competing products or services are available for inclusion

2.	Scientific objectivity of studies mentioned in the materials or used as the basis for content

3. Appropriateness of patient care recommendations made to learners

Privacy Policy

When you participate in an educational activity provided by the IMER (“we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”). We use that Information in the following ways:

We use the Information to grade your posttest and to send you a certificate of completion of the educational activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the Information to that company for that purpose only.

For each educational activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

We may use the Information to invite you to participate in other educational activities that IMER or its affiliates may offer.

On occasion, the commercial supporter of a educational activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in the educational activity (ie, who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will provide the supporter with your name, title and affiliation, but we will request in writing that the supporter not contact you directly for any purpose.

If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.

Any changes to our privacy policy will be posted here.

Method of Participation

There are no fees for participating and receiving nursing contact hours for this activity.

Participants must complete the posttest by recording the best answer to each question. Once you finished your test and completed the subsequent evaluation form, click submit test to send your responsed to us. Your test will be immediately reviewed and if you receive a passing grade of 70% or better, you will then be directed to print your certificate online.

Media

Web site